This 2 part study will evaluate the safety and efficacy of a combination of Avastin, Tarceva
and Xeloda (ATX) as second-line treatment in patients with locally advanced and/or metastatic
pancreatic cancer. In the first part of the study, cohorts of patients will receive
escalating doses of combination treatment to determine the maximum tolerated dose. The
recommended dose will be used in the second part of the study to determine the efficacy of
the ATX regime, in terms of its effect on disease progression. The anticipated time on study
treatment is 3-12 months, and the target sample size is <100 individuals.